The timing of treatment is crucial for conditions related to autism — and more so for some conditions than for others.

Researchers are edging closer to a therapy for Angelman syndrome — a condition related to autism — that involves injecting the gene-editing enzyme CRISPR into the fetal brain.

Modified stem cells show promise for delivering gene-based therapies to individuals with Angelman syndrome.

Compounds that mimic a cancer drug restore expression of the key gene mutated in Angelman syndrome, a condition related to autism.

The international manual of conditions now includes a diagnostic code for Angelman syndrome — which may enable scientists to systematically collect information about the syndrome.

A pruning protein reshapes neurons, culture should be a consideration in trials of autism treatments, and another U.S. state adds autism to the list of indications for medical cannabis.

Introducing the gene UBE3A into neurons that dampen brain activity prevents seizures in a mouse model of Angelman syndrome.

Mice with an extra copy of UBE3A, a gene linked to autism, have learning problems and anxiety, and are prone to seizures and fine-motor problems.

Having too many copies of an autism gene called UBE3A mutes a brain region that may mediate the satisfaction a person derives from social interactions.

Mice with an extra copy of the autism risk gene UBE3A have cognitive deficits and anxiety, but do not show any core features of the condition.